Addrenex Pharmaceuticals has filed a new drug application for its CloniBID™ product, which treats hypertension.
The Research Triangle Park-based company says its product treats hypertension without some of the unwanted side effects of current drugs. Also, the drug is believed to keep blood pressure more constant than existing medicines. Upon approval from the Food and Drug Administration, Addrenex and its licensing partner Sciele Pharma, Inc. will launch the drug in the first half of 2009.
Addrenex has a second drug in Phase III clinical trials, Clonicel for the treatment of attention deficit hyperactivity disorder. Trials are scheduled to be complete by the end of the year.
"We credit our rapid success in developing viable drugs and building partnerships to our nimble, fast-paced business model and outside-the-box thinking," said Moise Khayrallah, cofounder and CEO of Addrenex.
"We stay sharply focused on the major milestones that must be accomplished, and we don’t allow perceived impediments to hamper our progress."